Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT07382999
Recruiting Observational

Effect of Adherence to a Gluten-Free Diet on Cognitive and Motor Dual-Task Performance in Adolescents Diagnosed With Celiac Disease

NCT07382999 · tracked via the Priya Life Science Turkey tracker
Sponsor
Inonu University
Phase
Observational
Started
2026-02-12
Last updated
2026-09-09

Condition(s) studied

Celiac Disease in ChildrenCeliac Disease in Adolescents

Study summary

The aim of this cross-sectional observational study is to comprehensively examine the effects of adherence to a gluten-free diet on cognitive, motor, and psychosocial functions in adolescents aged 8-18 years diagnosed with celiac disease. In this context, dual-task gait performance, cognitive processing speed and attention, working memory and executive functions, muscle strength, quality of life, and fatigue levels of individuals with celiac disease who are adherent or non-adherent to a gluten-free diet will be compared with those of healthy peers. In addition, sleep patterns, pubertal development, socioeconomic indicators, and serological markers will be taken into account to evaluate the unique effects of diet adherence on neurocognitive and functional outcomes. All assessments will be conducted in accordance with a predefined standardized protocol. The order of measurement instruments will be randomized to minimize potential bias. Inclusion criteria will consist of being between 8 and 18 years of age, having a celiac disease diagnosis confirmed by serology, being followed with this diagnosis for at least six months, and obtaining written informed consent from both the participant and their parent/guardian. For the healthy control group, participants must be within the same age range and have no history of chronic neurological, psychiatric, or gastroenterological conditions. Data analysis will be performed using SPSS

Eligibility

Sex
ALL
Min age
8 Years
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Participants aged between 8 and 18 years with a serologically confirmed diagnosis of celiac disease * Who have been followed for at least six months after diagnosisn * For whom written informed consent has been obtained from both the participant and their parent/legal guardian, will be included in the study. * The healthy control group will consist of individuals in the same age range with no history of chronic neurological, psychiatric, or gastroenterological diseases. Exclusion Criteria: * Will include the presence of an acute infection or systemic disease * Diagnosed neurological disorders (such as epilepsy or cerebral palsy); * A history of severe psychiatric disorders; conditions that may interfere with test administration, including visual, hearing, or ambulatory impairments * Initiation of psychotropic medication or changes in the current dosage within the past four weeks; the presence of unstable metabolic or endocrine disorders * Failure to obtain the required informed consent for participation.

Primary outcome measure(s)

  • Dual-task 10-Meter Walk Test — baseline one assestmeant
    Following the administration of the 10-Meter Walk Test (10MWT), participants aged 6-11 years will be instructed to verbally name as many animals as they know until they are asked to stop during the test. For participants aged 12-18 years, the serial sevens task (counting backward by sevens starting from 100) will be administered concurrently with the 10MWT.

Trial sites (1)

FacilityCityRegionStatus
İnönü Üniversitesi Turgut Özal Tıp Merkezi Malatya Turkey (Türkiye) Recruiting

More Inonu University trials in Turkey

Effect of Augmented Low-dye* Taping and Exercise on Plantar Pressure, Navicular Drop and Foot Posture in Pes Planus Active, not recruiting
Liver Transplant Recipients and 30-Second Lie-to-Sit Test Recruiting
Blood Parameter Changes Following Aerobic Exercise in Professional Soccer Players Starting soon
The Effect of Web-based Education on Gynecological Cancer Awareness and Healthy Life Behaviors Enrolling by invitation
Nonpharmacological Management of Pain and Fear During Hormone Injection in Breast Cancer Patients Starting soon

Other trials for the same condition

Nutrition and Physical Activity Education in Children With Celiac Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07382999 on ClinicalTrials.gov ↗ ← All trials in Turkey